Sanofi's Riliprubart Granted Orphan Drug Status By FDA For Addressing Antibody-Mediated Rejection, A Major Unmet Need In Transplant Medicine

Sanofi SA Sponsored ADR

Sanofi SA Sponsored ADR

SNY

0.00

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

  • Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients
  • Riliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.